MedPath

Effect of brexpiprazole on sleep architecture in patients with schizophrenia

Not Applicable
Conditions
Patients with schizophrenia
Registration Number
JPRN-UMIN000049311
Lead Sponsor
Department of Psychiatry, Kurita Hospital
Brief Summary

Add-on brexpiprazole had the following effects on sleep architecture in patients with schizophrenia. The fraction of stage N2 increased by 14.0% (p = 0.018), and the duration increased by 49.9 min (p = 0.018). The fraction of stage N3 increased by 0.7% (p = 0.027), and the duration increased by 2.5 min (p = 0.034). Additionally, the fraction of stage REM sleep was reduced by 10.0% (p = 0.018), and the duration was decreased by 33.8 min (p = 0.018).

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
7
Inclusion Criteria

Not provided

Exclusion Criteria

1.Comorbidity with mood disorder, anxiety disorder, drug addiction, personality disorder 2.Comorbidity with serious physical diseases such as cerebrovascular disease, heart disease, renal dysfunction, neurological disease 2.Comorbidity with sleep disorders such as hypersomnia, sleep-related breathing disorders, circadian rhythm sleep disorders, parasomnias, and sleep-related movement disorders 3. Use of drugs that affect sleep electroencephalography (EEG), such as hypnotics, anxiolytics, mood stabilizers, antihistamines, steroids, etc. 4.Apnea Hypopnea Index (AHI) > 15/h; and Periodic Limb Movement Index (PLMI) > 15/h.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Sleep variables measured by PSG: comparison before intervention and after 4 weeks of brexpiprazole administration
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath